Search

Zentalis Pharmaceuticals Inc

Fechado

4.55 -5.01

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.44

Máximo

4.74

Indicadores-chave

By Trading Economics

Rendimento

-136K

-35M

EPS

-0.503

Funcionários

106

EBITDA

2.2M

-35M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+33.89% upside

Dividendos

By Acuity

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

34M

329M

Abertura anterior

9.56

Fecho anterior

4.55

Zentalis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jul. de 2026, 23:56 UTC

Intel Corp shares are lower in after-hours trading, reflecting broader market pressures amid a significant decline in Japan's Nikkei 225 Index.

16 de jul. de 2026, 23:56 UTC

ETF Constituents
Macro News

iShares China Large-Cap ETF trades lower in after-market hours amid rising U.S.-Iran tensions and weakness in technology stocks, with notable declines from TCOM and LI.

16 de jul. de 2026, 23:56 UTC

ETF Constituents
Macro News
Correlated Moves

The iShares MSCI Japan ETF is lower in after-market trading, reflecting declines in the Nikkei 225 index and key holdings like SONY and NMR.

16 de jul. de 2026, 23:52 UTC

Fed Vice Chair Jefferson signals potential interest rate reassessment amid persistent inflation concerns.

16 de jul. de 2026, 23:52 UTC

Michigan Consumer Sentiment Index for July 2026 Forecasted at 51.0 Amid Mixed Confidence and Inflation Concerns Ahead of Release.

16 de jul. de 2026, 23:52 UTC

Social Media
News

Netflix Inc. shares fell in after-hours trading following Q2 results. Revenue of $12.56 billion missed expectations, and guidance for 2026 was narrowed lower.

16 de jul. de 2026, 23:52 UTC

Social Media
Correlated Moves

NVIDIA Corp shares declined in after-market hours, reflecting broader market downturn and geopolitical tensions. The stock underperformed against major tech peers during the session.

16 de jul. de 2026, 23:51 UTC

Global equity markets decline as Nikkei 225 drops 2.8%, while U.S. jobless claims fall unexpectedly and manufacturing activity surges, amid concerns over slowing retail sales and geopolitical tensions.

16 de jul. de 2026, 23:51 UTC

Mixed trading in European equities amid geopolitical tensions and mixed earnings; U.S. tech stocks decline as jobless claims fall unexpectedly.

16 de jul. de 2026, 23:51 UTC

U.S. equity markets remain flat amid geopolitical tensions and mixed economic data, with Nasdaq down 1.5% as oil prices surge above $80 per barrel.

16 de jul. de 2026, 23:51 UTC

Asia equity markets mixed as Japan's Nikkei drops 2.8% on tech weakness, while GBP/USD falls amid geopolitical tensions and U.S. tech stocks face pressure from disappointing earnings.

16 de jul. de 2026, 23:46 UTC

Social Media

Shares of Electronic Arts Inc are lower in after-market trading, reflecting a decline from earlier gains. Upcoming EA SPORTS FC 27 release is drawing attention.

16 de jul. de 2026, 23:46 UTC

News

Paychex declared a quarterly dividend of $1.19 per share, payable August 28, contributing to positive sentiment as shares rise in after-market trading.

16 de jul. de 2026, 23:46 UTC

Cintas Corp shares are higher in after-market hours. Broader market sentiment may be supported by recent labor market strength and modest retail sales growth.

16 de jul. de 2026, 23:46 UTC

ETF Constituents
News
Correlated Moves

Vanguard Growth ETF declines after-hours, impacted by Netflix's drop and broader Nasdaq 100 downturn amid rising inflation concerns and central bank comments.

16 de jul. de 2026, 23:46 UTC

American Airlines Group Inc. shares are lower in after-market trading, reflecting routine fluctuations and remaining below the 20-day moving average.

16 de jul. de 2026, 23:42 UTC

Cisco shares traded higher during after-market hours, reflecting internal dynamics. The stock's activity remained routine amid broader declines in major technology stocks.

16 de jul. de 2026, 23:41 UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

16 de jul. de 2026, 23:41 UTC

Lululemon shares declined in after-market trading, continuing a downward trend since Thursday's close amid weakness in major technology stocks.

16 de jul. de 2026, 23:41 UTC

News
Correlated Moves

Lam Research Corp shares are lower in after-market trading amid a sector-wide selloff following TSMC's capital expenditure announcement and bearish sentiment from options traders.

16 de jul. de 2026, 23:41 UTC

Correlated Moves

KLA Corp shares are lower in after-market hours, reflecting broader market declines amid weakness in major technology stocks and renewed semiconductor sector volatility.

16 de jul. de 2026, 23:41 UTC

ETF Constituents
Macro News
Correlated Moves

Financial Select Sector SPDR Fund trades lower in after-market hours amid broader market decline and rising tensions between the U.S. and Iran.

16 de jul. de 2026, 23:41 UTC

Trip.com Group Ltd shares are lower in after-market hours amid broader market declines, particularly in technology stocks and heightened economic uncertainty.

16 de jul. de 2026, 23:41 UTC

Baidu Inc. shares are trading lower in after-market hours, reflecting broader market declines amid volatility in the semiconductor sector and geopolitical tensions.

16 de jul. de 2026, 23:41 UTC

JD.Com Inc. shares are higher in after-market trading, supported by gains in the Broadline Retail sub-sector. The stock remains above its 20-day moving average.

16 de jul. de 2026, 23:41 UTC

Correlated Moves

Analog Devices Inc remains unchanged in after-market trading amid declines in the Nasdaq 100 Index and weakness among major technology stocks.

16 de jul. de 2026, 23:41 UTC

Macro News
Correlated Moves

Ethereum is trading lower as U.S. markets decline amid technology sector weakness and rising geopolitical tensions, impacting global sentiment in cryptocurrencies.

16 de jul. de 2026, 23:41 UTC

Macro News
Correlated Moves

Bitcoin declines amid rising U.S.-Iran tensions and market volatility. The Crypto Fear & Greed Index shows extreme fear among investors, contributing to uncertainty.

16 de jul. de 2026, 23:41 UTC

Booking Holdings Inc. shares are higher in after-market trading, maintaining levels above the 20-day moving average amid slight fluctuations since Thursday's close.

16 de jul. de 2026, 23:36 UTC

Ross Stores Inc. shares declined in after-market trading amid weakness in major technology stocks. The asset is lower since Thursday's close.

Comparação entre Pares

Variação de preço

Zentalis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

33.89% parte superior

Previsão para 12 meses

Média 6.4 USD  33.89%

Máximo 10 USD

Mínimo 4 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

3

Comprar

3

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat